Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Clinical trial NCT07013565 · RECRUITING

Trial details

NCT number: NCT07013565
Sponsor: New York Medical College
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Anaplastic Large Cell Lymphoma, ALK-Positive

Start date: 2025-08-07
Primary completion: 2029-07-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.